{"id":7201,"date":"2025-11-20T11:05:33","date_gmt":"2025-11-20T16:05:33","guid":{"rendered":"https:\/\/cqdm.org\/?post_type=project&#038;p=7201"},"modified":"2025-11-20T11:09:05","modified_gmt":"2025-11-20T16:09:05","slug":"development-of-an-advanced-multiplexed-lab-on-a-chip-system-for-high-throughput-screening-using-organ-on-a-chip-technology-to-support-ai-drug-discovery","status":"publish","type":"project","link":"https:\/\/cqdm.org\/en\/achievement\/funded-projects\/development-of-an-advanced-multiplexed-lab-on-a-chip-system-for-high-throughput-screening-using-organ-on-a-chip-technology-to-support-ai-drug-discovery\/","title":{"rendered":"Development of an advanced multiplexed lab-on-a-chip system for high-throughput screening using organ-on-a-chip technology to support AI drug discovery"},"content":{"rendered":"\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"is-style-suptitle\">Principal Investigator<\/p>\n\n\n\n<p><strong><strong>Jacques Corbeil<\/strong><\/strong><br>Universit\u00e9 Laval \u2013 CHU de Qu\u00e9bec-Universit\u00e9 Laval and an affiliate member of MILA<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"is-style-suptitle\">Co-chercheur<\/p>\n\n\n\n<p><strong>Teodor Veres<\/strong><br>National Research Council of Canada<\/p>\n<\/div>\n<\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" id=\"block-f144a6d1-0fff-4954-bbb0-b6887311b986\"\/>\n\n\n\n<p class=\"is-style-intro\" id=\"block-0b024f00-3d65-4535-9656-7964e0bd141d\">Project of $343,268 over 1 year<\/p>\n\n\n\n<ul class=\"wp-block-list is-style-checkmark\">\n<li><strong>Supported by CQDM through:<\/strong><br>Minist\u00e8re de l\u2019\u00c9conomie, de l\u2019Innovation et de l\u2019\u00c9nergie du Qu\u00e9bec (MEIE)<\/li>\n\n\n\n<li><strong>And by co-funding partners:<\/strong><br>&#8211; Linearis Labs Inc.<br>&#8211; Canada Biomedical Research Fund (CBRF)<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" id=\"block-22757ac3-7e91-4e37-97af-3f8b9f955d83\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"block-c24b9fa8-8b68-4be5-940f-0f03a6109871\">The project in detail:<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Challenge<\/h3>\n\n\n\n<p id=\"block-ff7da0e8-a888-49f9-87ee-d6876dc4fcc6\">The goal of the project is to bridge the gap between generative artificial intelligence in drug discovery and laboratory capabilities to monitor relevant metabolites in health and disease states, in order to improve the efficacy and reduce the toxicity of newly developed drugs.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Solution<\/h3>\n\n\n\n<p id=\"block-ff7da0e8-a888-49f9-87ee-d6876dc4fcc6\">The solution lies in organ-on-a-chip (OOC) systems, which offer a powerful platform for biomedical research by recreating functional units of human organs for in vitro testing. OOCs provide key advantages over conventional in vivo preclinical models. They offer physiologically realistic models, high-throughput processing capabilities that enable the use of AI algorithms, lower costs compared to in vivo studies, and real-time quantitative evaluation using metabolomics, proteomics, and imaging. These organ-on-a-chip systems are easy to handle and highly faithful, allowing for better mimicry of human organs. OOCs represent a promising alternative to complement in vivo modelling in preclinical drug and toxicity screening.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Expected Achievements \/Impacts<\/h3>\n\n\n\n<p id=\"block-ff7da0e8-a888-49f9-87ee-d6876dc4fcc6\">Research teams from the Medical Devices Research Centre at the NRC and the CHU de Qu\u00e9bec\u2013Universit\u00e9 Laval will accelerate the drug development process and gain better insights into drug toxicity, through an advanced microfluidic-based device designed and built by NRC. The OOCs will be manufactured in Qu\u00e9bec and distributed exclusively by Linearis, a Qu\u00e9bec-based company, for the benefit of patients. A testing platform will be established and made available to pharmaceutical companies and startups worldwide to test their compounds and facilitate access to funding, supported by robust results that go beyond the limitations of in vivo models.<\/p>\n","protected":false},"featured_media":3832,"template":"","project-category":[94],"class_list":["post-7201","project","type-project","status-publish","has-post-thumbnail","hentry","project-category-platforms-and-databases"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project\/7201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/project"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/3832"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=7201"}],"wp:term":[{"taxonomy":"project-category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project-category?post=7201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}